secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001193125-24-164004
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma increases Evrysdi royalty stake to 90.5% for $242M from PTC option exercise
--------------------------------------------------------------------------------

- PTC exercised option to sell half its retained Evrysdi royalty to Royalty Pharma for ~$242M upfront.
- Royalty Pharma's Evrysdi royalty ownership increases from 81% to 90.5% (before cap).
- Evrysdi (SMA drug) generated 2023 sales of ~CHF 1.4B ($1.6B), up 39% YoY at CER.
- Total upfront investment in Evrysdi royalties now $1.9B; effective royalty rate 7.2%-14.5%.
- PTC retains option to sell remaining 9.5% royalty for $250M less royalties received until Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524164004/0001193125-24-164004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524164004/d724682d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-164004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer